Clinical trials: Kidney Neoplasms / Surgery

Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.

Conditions

Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7

Trial name

ASSURE (NCT00326898)

Testing

Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate

Where

987 sites in United States, Canada and 1 more

Volunteers

1,943 people

Sponsor

National Cancer Institute (NCI)